Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Safety, Tolerability and Antiviral Activity of 12 Weeks' Treatment With a New Antiviral HCMV Drug

NCT01063829 is registered in ClinicalTrials.gov with AiCuris Anti-infective Cures AG as lead sponsor.

NCT NCT01063829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01063829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Safety, Tolerability and Antiviral Activity of 12 Weeks' Treatment With a New Antiviral HCMV Drug
Lead sponsor
AiCuris Anti-infective Cures AG
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2010
Completion date
December 31, 2011
Enrollment
133 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

hcmv reactivation or hcmv end-organ disease